Patents by Inventor Hans-Peter Vornlocher

Hans-Peter Vornlocher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glycoconjugates of RNA interference agents
    Patent number: 10131907
    Abstract: The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: November 20, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Andrea Forst, Philipp Hadwiger, Hans-Peter Vornlocher
  • MULTIMERIC OLIGONUCLEOTIDES HAVING DECREASED KIDNEY CLEARANCE
    Publication number: 20180223284
    Abstract: The present invention relates to methods of administering to a subject multimeric oligonucleotides having monomeric subunits joined by linkers. The multimeric oligonucleotides have a molecular weight of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present invention also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.
    Type: Application
    Filed: February 6, 2018
    Publication date: August 9, 2018
    Inventors: Kristin K. H. Neuman, Jonathan Miles Brown, Hans-Peter Vornlocher
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20180148726
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: January 18, 2018
    Publication date: May 31, 2018
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Compositions and Methods for Inhibiting Expression of Factor V
    Publication number: 20180127749
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: August 14, 2017
    Publication date: May 10, 2018
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 9914927
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 13, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Compositions and Methods for Inhibiting Expression of Factor V
    Publication number: 20170121709
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: August 18, 2016
    Publication date: May 4, 2017
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20160376599
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 9476052
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: October 25, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Compositions and methods for inhibiting expression of factor V
    Patent number: 9441225
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: September 13, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Compositions and Methods for Inhibiting Expression of Eg5 Gene
    Publication number: 20160017337
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Application
    Filed: May 22, 2015
    Publication date: January 21, 2016
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • RNAi modulation of ApoB and uses thereof
    Patent number: 9187747
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: November 17, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAi Inhibition of A1pha-ENaC Expression
    Publication number: 20150284726
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: June 3, 2015
    Publication date: October 8, 2015
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi inhibition of alpha-ENaC expression
    Patent number: 9074212
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: July 7, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • Compositions and methods for inhibiting expression of Eg5 gene
    Patent number: 9057069
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: June 16, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • Nuclease resistant double-stranded ribonucleic acid
    Patent number: 8993746
    Abstract: This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: March 31, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, Ingo Roehl, Philipp Hadwiger, Tracy Stage Zimmermann, Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc
  • Glycoconjugates of RNA Interference Agents
    Publication number: 20150065558
    Abstract: The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
    Type: Application
    Filed: September 29, 2014
    Publication date: March 5, 2015
    Inventors: Andrea Forst, Philipp Hadwiger, Hans-Peter Vornlocher
  • Glycoconjugates of RNA interference agents
    Patent number: 8877917
    Abstract: The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: November 4, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Andrea Forst, Philipp Hadwiger, Hans-Peter Vornlocher
  • Compositions And Methods For Inhibiting Expression of Factor V
    Publication number: 20140206747
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: January 14, 2014
    Publication date: July 24, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Compositions and methods for inhibiting expression of factor V
    Patent number: 8658782
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: February 25, 2014
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • RNAi Modulation Of ApoB And Uses Thereof
    Publication number: 20140045922
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir